ILMN · Illumina, Inc. · Stock research

Current Thesis

The give-back that defined the early-August tape is gone. After closing $187.96 on 2026-08-07 — 8.4% below the $205.10 high made into the 2026-07-30 print — the stock reclaimed that shelf and closed 2026-08-21 at $219.40, a 52-week high, with RSI(14) at 66.3 and a three-month price change of +51.9%. What did not change is the information set: the last company-dated fundamental input remains the Q2 FY26 report of 2026-07-30 (revenue $1.159B, +9.4% YoY vs $1.130B consensus; adjusted EPS $1.31 vs $1.23; FY26 raised to $4.600–4.640B and $5.30–$5.40). The August advance was driven by positioning and financing headlines rather than new operating news — a syndicated credit agreement dated 2026-08-13, $300M of 4.950% notes due 2029 issued 2026-08-17, and new institutional stakes disclosed during the August 13F cycle (ad-hoc-news, 2026-08-20). The narrative leg an investor is buying is unchanged: NovaSeq X installed-base conversion turning into recurring clinical consumables over the next three to four quarters. Life-cycle stays maturing — the leg still works, but the price is now moving without fresh fundamental information, coverage is near-universal, and the tape has passed the sell-side's own average target. Nothing company-dated is confirmed before the Q3 print in late October.

Bullish and bearish views on Illumina, Inc.

The model's bull view on Illumina, Inc. (ILMN), in brief: Q2 FY26 (2026-07-30): revenue $1.159B, +9.4% YoY, ahead of the $1.130B consensus; adjusted EPS $1.31 vs $1.23 estimated; organic growth 6.5% YoY, a step up from the +4.8% blended Q1 FY26 print (2026-04-30). The bear view: Price has passed the published targets. The 2026-08-20 write-up citing analyst consensus put the average target at $198.89, with other August compilations at $194.93 and $195.83 (19 analysts, S&P Global, consensus rating Hold). Only the top cluster — RBC $230 and JPMorgan $230… Both cases follow in full.

Bull Case

• Q2 FY26 (2026-07-30): revenue $1.159B, +9.4% YoY, ahead of the $1.130B consensus; adjusted EPS $1.31 vs $1.23 estimated; organic growth 6.5% YoY, a step up from the +4.8% blended Q1 FY26 print (2026-04-30).
• Guidance raised on both lines the same day: FY26 revenue $4.600–4.640B (from $4.520–4.620B), adjusted EPS $5.30–$5.40 (from $5.15–$5.30); Q3 FY26 revenue set at $1.14–1.16B.
• Clinical consumables +15% YoY excluding China in Q2 FY26; clinical is roughly 65% of sequencing consumables revenue, with US/Canada clinical growth above 20%.
• Conversion is measured, not projected: ~83% of sequencing volumes and ~59% of sequencing revenue on NovaSeq X as of Q2 FY26, 95+ instruments placed in the quarter, 80–85% clinical volume conversion targeted by end-2026. Management's stated six-to-nine-month pull-through lag makes that Q2 cohort a 2027 consumables input already installed.
• Adjusted operating income $260M in Q2 FY26, a 22.4% adjusted operating margin.
• Funding was taken in the debt market into strength, not the equity market: a new syndicated credit agreement with Bank of America as administrative agent dated 2026-08-13, and $300M aggregate principal of 4.950% notes due 2029 issued 2026-08-17. A $1.5B repurchase authorization was approved 2026-04-28.
• The trend structure confirmed rather than failed: the 2026-07-30 print-day high of $205.10 capped the tape for three weeks, then the close on 2026-08-19 was $205.00 (an 8.91% five-day gain), an intraday $214.30 was cited on 2026-08-20, and the 2026-08-21 close was $219.40.

Bear Case

• Price has passed the published targets. The 2026-08-20 write-up citing analyst consensus put the average target at $198.89, with other August compilations at $194.93 and $195.83 (19 analysts, S&P Global, consensus rating Hold). Only the top cluster — RBC $230 and JPMorgan $230 (2026-07-31), Guggenheim $226, Stifel $225 (2026-07-31), Piper Sandler $225 (2026-08-03) — sits above the 2026-08-21 close of $219.40.
• The bear seat is still occupied at the extremes: Citigroup kept Sell while lifting to $113 (2026-08-03) and Barclays stayed Underweight at $160 (2026-07-31). A $113-to-$230 spread on the same quarter is not a consensus that has resolved.
• The +51.9% three-month advance rests on one operating datapoint. Between 2026-08-07 ($187.96) and 2026-08-21 ($219.40) the company disclosed financing arrangements and nothing about demand.
• Multiple expansion is doing the work: the same $5.30–$5.40 FY26 adjusted EPS band supported a $187.96 close on 2026-08-07 and a $219.40 close on 2026-08-21, on 6.5% organic growth.
• The research & applied book was -12% YoY in Q1 FY26 and is guided to a mid-to-high-single-digit FY26 decline, against a mix that is roughly 44% academic and government. The US federal fiscal year ends 2026-09-30.
• Headline clinical growth is quoted ex-China. China is outside the +15% figure and has not been quantified separately at the last two prints.
• Those sales were struck well below where the stock closed 2026-08-21.

Setup & Price Structure

• The 2026-08-21 close of $219.40 is the 52-week high; distance from the high is 0.0%. RSI(14) at 66.3 is elevated but short of the 70 line, and it has expanded from 52.5 on 2026-08-07.
• Path since the print: $205.09 the session before Q2, $202.95 the session after (2026-07-30), $187.96 on 2026-08-07, $205.00 on 2026-08-19, $219.40 on 2026-08-21. The $205.10 July peak is the first structural shelf beneath the market; the $188 area is the floor of the post-print range that preceded the breakout.
• Crowding observables, stated as observables: price sits above the average sell-side target of roughly $195–$199 quoted in mid-August; the news flow of 2026-08-19/20 was price-generated rather than event-generated (headlines describing an 8.9% move and investors "revisiting" a three-week-old quarter); new institutional stakes were disclosed during the August 13F cycle; the company issued $300M of 4.950% 2029 notes on 2026-08-17 into the advance; and there is no earnings date inside the next 30 days to force positioning either way.
• What the structure does not have: a base. The move from $187.96 to $219.40 took ten sessions with no consolidation, so the nearest reference for a failed breakout is the $205.10 shelf and then the $188–$205 range under it.
• The advance ran through an unsettled broad tape — the 2026-08-20 session carried a 9% Walmart drawdown and a failed bond-market stabilisation as the market-wide headlines — which argues the bid was name-specific.

Catalyst Calendar (next 30 days)

• No company-dated event is confirmed between 2026-08-22 and 2026-09-21. No earnings, no announced investor-day, no regulatory decision on the calendar for that window.
• 2026-09-30 — US federal fiscal year end / appropriations deadline. Outside the 30-day window by nine days, but it is the next dated input to the ~44% academic-and-government mix and to the research & applied book.
• ~2026-10-29 (est.) — Q3 FY26 print. Date unconfirmed; Q1 landed 2026-04-30 and Q2 landed 2026-07-30. It tests the $1.14–1.16B Q3 revenue guide and the first conversion of the 95+ NovaSeq X units placed in Q2.

What Would Change Our Mind

The structure that would have to fail first is the shelf the stock just cleared: the $205.10 print-day high from 2026-07-30, and beneath it the $188–$205 range that held for three weeks. A weekly close below $196 puts price back inside that range and marks the August breakout as a failed one rather than a base. On the fundamentals, Q3 revenue under the $1.14B guide floor set 2026-07-30, or clinical consumables ex-China decelerating below mid-teens YoY, would remove the growth step the re-rating was paid for. Two further items would flip the read: new Corvex Form 4 open-market sales struck above the May–June $147.50–$165.50 band, and downgrades converging toward the Citigroup $113 / Barclays $160 end after the Q3 print. In the other direction, a Q3 beat that holds the guide with a China figure disclosed would move the leg back toward accelerating; the absence of any company-dated news through late October, with price above the consensus target, moves it toward saturated.

Correlation Notes

• Trades with the life-science tools and sequencing complex on NIH and appropriations headlines rather than with AI or semiconductor tape; the 2026-09-30 fiscal-year deadline is a sector-wide input, not an ILMN-specific one.
• Roughly 44% academic and government mix makes federal budget authority the dominant macro beta; the research & applied line (-12% YoY in Q1 FY26) is where that shows up first.
• China policy is a separate axis, currently carved out of the headline clinical growth rate, so a China escalation would hit reported revenue without changing the ex-China number management quotes.
• Long-duration medtech multiple is rate-sensitive; the 4.950% coupon on the notes issued 2026-08-17 is a dated mark on the company's cost of funds.
• Idiosyncratic overlay: an activist with a board seat means Corvex Form 4s remain the cleanest public read on supply, independent of sector flow.